DK452289D0 - Praeparat eller system til behandling af diabetes - Google Patents

Praeparat eller system til behandling af diabetes

Info

Publication number
DK452289D0
DK452289D0 DK452289A DK452289A DK452289D0 DK 452289 D0 DK452289 D0 DK 452289D0 DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A DK 452289 D0 DK452289 D0 DK 452289D0
Authority
DK
Denmark
Prior art keywords
insulin
function
liver
targeted
encapsulated
Prior art date
Application number
DK452289A
Other languages
English (en)
Other versions
DK452289A (da
Inventor
Walter Blair Geho
Original Assignee
Technology Unlimited Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Unlimited Inc filed Critical Technology Unlimited Inc
Publication of DK452289D0 publication Critical patent/DK452289D0/da
Publication of DK452289A publication Critical patent/DK452289A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK452289A 1988-01-13 1989-09-13 Praeparat eller system til behandling af diabetes DK452289A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/143,180 US4863896A (en) 1984-05-03 1988-01-13 Diabetic control by combined insulin forms
PCT/US1988/001536 WO1989006540A1 (en) 1988-01-13 1988-05-13 Diabetic control by combined insulin forms

Publications (2)

Publication Number Publication Date
DK452289D0 true DK452289D0 (da) 1989-09-13
DK452289A DK452289A (da) 1989-11-09

Family

ID=22502938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK452289A DK452289A (da) 1988-01-13 1989-09-13 Praeparat eller system til behandling af diabetes

Country Status (8)

Country Link
US (1) US4863896A (da)
EP (1) EP0358709B1 (da)
AT (1) ATE78169T1 (da)
AU (1) AU622370B2 (da)
DE (1) DE3872878T2 (da)
DK (1) DK452289A (da)
FI (1) FI894376A0 (da)
WO (1) WO1989006540A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
WO1999016425A1 (en) * 1997-09-30 1999-04-08 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US6159931A (en) * 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
JP5452843B2 (ja) 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド 夜間の経口インスリン治療
US20050203001A1 (en) 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
CA2536393A1 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample
EP2626368B1 (en) * 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1883394B1 (en) * 2005-05-23 2018-03-28 SDG, Inc. Lipid construct for delivery of insulin to a mammal
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
RU2453332C2 (ru) 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
WO2010080976A1 (en) * 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
CN105753965A (zh) 2009-01-28 2016-07-13 斯马特塞尔斯公司 用于受控药物递送的基于缀合物的系统
BRPI1007466A2 (pt) 2009-01-28 2018-06-12 Smartcells Inc conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AU2011282987A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
KR20160065930A (ko) 2013-10-04 2016-06-09 머크 샤프 앤드 돔 코포레이션 글루코스-반응성 인슐린 접합체
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
BR112019018989A2 (pt) 2017-03-13 2020-04-14 Sdg Inc nanopartículas à base de lipídeo com estabilidade melhorada
US10918700B2 (en) * 2019-04-12 2021-02-16 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system

Also Published As

Publication number Publication date
AU1790588A (en) 1989-08-11
EP0358709A4 (en) 1990-03-08
ATE78169T1 (de) 1992-08-15
DE3872878T2 (de) 1992-12-03
EP0358709B1 (en) 1992-07-15
FI894376A0 (fi) 1989-09-15
AU622370B2 (en) 1992-04-02
EP0358709A1 (en) 1990-03-21
DK452289A (da) 1989-11-09
DE3872878D1 (de) 1992-08-20
US4863896A (en) 1989-09-05
WO1989006540A1 (en) 1989-07-27

Similar Documents

Publication Publication Date Title
DK452289A (da) Praeparat eller system til behandling af diabetes
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DK0480934T3 (da) Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt
FI875533A (fi) Insulinpreparat foer non-parenteral dosering.
FI880409A0 (fi) Transdermalt absorberande doseringsenhet foer estradiol och andra estrogena steroider och administrationsfoerfarande.
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
DE59808186D1 (de) Transdermales therapeutisches system zur abgabe von hormonen
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
ES2107511T3 (es) Procedimiento para la preparacion de un concentrado de factor xi de la coagulacion sanguinea con alta actividad especifica, apropiado para su uso terapeutico.
PT651654E (pt) Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa
AR003979A1 (es) Administracion transdermica de vorozol.
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
SE9101341D0 (sv) New medicinal use
Kobrine et al. Further studies on histamine in spinal cord injury and post traumatic hyperemia
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
Vovin et al. Therapeutic pathomorphosis of affective psychoses during the process of long-term treatment with lithium salts
黄涛生 et al. Changes in Protein Metabolism of Soleus Muscle in Scalded Rats and the Therapeutic Effects of Leucine and Insulin
施炳培 et al. THE RADIATION OF THE HE-NE LASER ON ACUPOINTS IN TREATMENT OF INFANTILE CHRONIC DIARRHEA IN 93 CASES
Ringenberg et al. The Clinical Use of Interferons.
ES256653U (es) Prenda terapeutica perfeccionada
RU96104613A (ru) Способ лечения больных эндокринной офтальмопатией

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment